Pacira Pharma (PCRX) Misses Q1 EPS by 104c

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of ($0.43), $1.04 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $160.3 million versus the consensus estimate of $159.1 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Sharon AI surges premarket; New Oriental gains, Medline slips
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital